Beauty

Shiseido to Sell China's Aupres Business to IDG-Led Consortium

The Japanese cosmetics group is divesting Shiseido Liyuan Cosmetics, including a Beijing factory, as it shifts resources to priority brands and higher-growth areas.

Dalia MansourNovember 19, 20265 min read2 views

A conceptual still life shows generic skincare containers linked by a handover line to an investment folder and a factory silhouette, representing the sale of a beauty business.

Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. Financial terms were not disclosed.

The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Under the agreed structure, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles. A limited partnership set up mainly by SLC's new management team will hold the remaining 5%.

Divestment tied to 2030 strategy

Shiseido framed the sale as part of its push to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. The company said it aims to drive sustainable growth and strengthen competitiveness in China by concentrating management resources on areas where it enjoys the greatest competitive advantage. The sale sheds a business that Shiseido says needs continued investment in product innovation and digital capabilities, allowing the group to focus on priority brands and higher-growth opportunities.

Shiseido described China as strategically important and attractive, while noting that e-commerce expansion, changing consumer behavior and the emergence of diverse market participants are reshaping competition there.

Aupres joint venture history

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group owned by the Beijing Municipal Government. It has sold the C-beauty brand Aupres since 1994. With the joint venture agreement due to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, giving it full ownership ahead of the sale.

Factory, IP and transition support included

The deal includes SLC's Beijing factory and production equipment. Shiseido said it believes independent operation under IDG will support SLC's sustainable growth and brand value. To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will provide support on new product development, technical assistance for stable supply of existing products, and continued supply of raw materials and selected products. The company said the arrangements aim to maintain SLC's innovation capabilities, product quality and business continuity.

Profit recovery precedes sale

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). It attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million) on the back of those results.